PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 11, 2026New England Journal of Medicine2 citations

A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia

View Full Paper
DKDavid J. KuterKMKatsuhiro MiuraAPAndrea Patriarca

Key Points

  • To assess the efficacy and safety of mezagitamab in increasing platelet counts in primary immune thrombocytopenia (ITP).
  • Phase 2 randomized trial design
  • Participants with persistent or chronic ITP
  • Comparison of mezagitamab against placebo
  • Measurement of platelet counts and safety profile
  • Mezagitamab treatment led to increased platelet counts
  • Safety profile of mezagitamab similar to placebo

Abstract

Treatment with mezagitamab led to increased platelet counts, with a safety profile that appeared to be similar to that of placebo among participants with persistent or chronic ITP. (Funded by Takeda Development Center Americas; ClinicalTrials.gov number, NCT04278924.).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Kuter et al. (2026) studied this question.

synapsesocial.com/papers/69d9e47378050d08c1b75122https://doi.org/10.1056/nejmoa2513120
Ask AI
Helpful
Bookmark
Share
View Full Paper